Chemotherapy and irradiation interaction

Seminars in Oncology

Volumn 30, Issue 4 SUPPL. 9, 2003, Pages 3-10

  Choy, Hak ^a   Kim, Dong W ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 9 AMINOCAMPTOTHECIN; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; CARBOPLATIN; DNA TOPOISOMERASE INHIBITOR; GEMCITABINE; IRINOTECAN; MITOMYCIN; NUCLEOSIDE ANALOG; PACLITAXEL; PLATINUM DERIVATIVE; PYRIMIDINE DERIVATIVE; TAXANE DERIVATIVE; TIRAPAZAMINE; TOPOTECAN;

CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; DRUG MECHANISM; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0042737503     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00268-9     Document Type: Article

References (71)

1. Steel GG, Peckham MJ: Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity. Int J Radiat Oncol Biol Phys 5:85-91, 1979
2. Kinsella TJ, Dobson PP, Mitchell JB, et al: Enhancement of X ray induced DNA damage by pre-treatment with halogenated pyrimidine analogs. Int J Radiat Oncol Biol Phys 13:733-739, 1987
3. Little JB, Hahn GM, Frindel E, et al: Repair of potentially lethal radiation damage in vitro and in vivo. Radiology 106:689-694, 1973
4. Wang Y, Pantelias GE, Iliakis G: Mechanism of radiosensitization by halogenated pyrimidines: The contribution of excess DNA and chromosome damage in BrdU radiosensitization may be minimal in plateau-phase cells. Int J Radiat Biol 66:133-142, 1994
5. Plunkett W, Huang P, Xu YZ, et al: Gemcitabine: Metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22:3-10, 1995 (suppl 11)
6. Lawrence TS, Eisbruch A, Shewach DS: Gemcitabine-mediated radiosensitization. Semin Oncol 24:S7-24-S7-28, 1997 (suppl 7)
7. Gregoire V, Hittelman WN, Rosier JF, et al: Chemoradiotherapy: Radiosensitizing nucleoside analogues (review). Oncol Rep 6:949-957, 1999
8. Milas L, Fujii T, Hunter N, et al: Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 59:107-114, 1999
9. Terasima T, Tolmach LJ: Variations in survival responses of HeLa cells to x-irradiation during the division cycle. Biophys J 3:11-33, 1963
10. Tishler RB, Geard CR, Hall EJ, et al: Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 52:3495-3497, 1992
11. Choy H, Rodriguez FF, Koester S, et al: Investigation of taxol as a potential radiation sensitizer. Cancer 71:3774-3778, 1993
12. Milas L, Hunter NR, Mason KA, et al: Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res 55:3564-3568, 1995
13. Milas L, Milas MM, Mason KA: Combination of taxanes with radiation: Preclinical studies. Semin Radiat Oncol 9:12-26, 1999 (suppl 1)
14. Brizel DM, Scully SP, Harrelson JM, et al: Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56:941-943, 1996
15. Brown JM, Giaccia AJ: The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res 58:1408-1416, 1998
16. Vaupel P, Kallinowski F, Okunieff P: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res 49:6449-6465, 1989
17. Tannock IF, Rotin D: Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 49:4373-4384, 1989
18. Hermens AF, Barendsen GW: The proliferative status and clonogenic capacity of tumour cells in a transplantable rhabdomyosarcoma of the rat before and after irradiation with 800 rad of X-rays. Cell Tissue Kinet 11:83-100, 1978
19. Stephens T, Steel GG: Regeneration of tumors after cytotoxic treatment, in Meyn R, Withers HR (eds): Radiation Biology in Cancer Research. New York, NY, Raven, 1980, pp 295-385
20. Milas L, Nakayama T, Hunter N, et al: Dynamics of tumor cell clonogen repopulation in a murine sarcoma treated with cyclophosphamide. Radiother Oncol 30:247-253, 1994
21. Douple EB, Richmond RC, Logan ME: Therapeutic potentiation in a mouse mammary tumour and an intracerebral rat brain tumour by combined treatment with cis-dichlorodiammineplatinum(II) and radiation. J Clin Hematol Oncol 7:585-603, 1977
22. Carde P, Laval F: Effect of cis-dichlorodiammine platinum Il and x rays on mammalian cell survival. Int J Radiat Oncol Biol Phys 7:929-933, 1981
23. O'Hara JA, Douple EB, Richmond RC: Enhancement of radiation-induced cell kill by platinum complexes (carboplatin and iproplatin) in V79 cells. Int J Radiat Oncol Biol Phys 12:1419-1422, 1986
24. Begg AC, van der Kolk PJ, Emondt J, et al: Radiosensitization in vitro by cis-diammine (1,1-cyclobutanedicarboxylato) platinum(II) (carboplatin, JM8) and ethylenediamminemalonatoplatinum(II) (JM40). Radiother Oncol 9:157-165, 1987
25. Amorino GP, Hamilton VM, Choy H: Enhancement of radiation effects by combined docetaxel and carboplatin treatment in vitro. Radiat Oncol Invest 7:343-352, 1999
26. Mason KA, Kishi K, Hunter N, et al: Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo. Clin Cancer Res 5:4191-4198, 1999
27. Omura M, Torigoe S, Kubota N: SN-38, a metabolite of the camptothecin derivative CPT-11, potentiates the cytotoxic effect of radiation in human colon adenocarcinoma cells grown as spheroids. Radiother Oncol 43:197-201, 1997
28. Chen AY, Okunieff P, Pommier Y, et al: Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives. Cancer Res 57:1529-1536, 1997
29. Amorino GP, Hercules SK, Mohr PJ, et al: Preclinical evaluation of the orally active camptothecin analog, RFS-2000 (9-nitro-20(S)-camptothecin) as a radiation enhancer. Int J Radiat Oncol Biol Phys 47:503-509, 2000
30. Grau C, Overgaard J: Radiosensitizing and cytotoxic properties of mitomycin C in a C3H mouse mammary carcinoma in vivo. Int J Radiat Oncol Biol Phys 20:265-269, 1991
31. Brown JM: The hypoxic cell: A target for selective cancer therapy-Eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 59:5863-5870, 1999
32. Gregoire V, Beauduin M, Bruniaux M, et al: Radiosensitization of mouse sarcoma cells by fludarabine (F-ara-A) or gemcitabine (dFdC), two nucleoside analogues, is not mediated by an increased induction or a repair inhibition of DNA double-strand breaks as measured by pulsed-field gel electrophoresis. Int J Radiat Biol 73:511-520, 1998
33. Lawrence TS, Chang EY, Hahn TM, et al: Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys 34:867-872, 1996
34. Latz D, Fleckenstein K, Eble M, et al: Radiosensitizing potential of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) within the cell cycle in vitro. Int J Radiat Oncol Biol Phys 41:875-882, 1998
35. Mason KA, Milas L, Hunter NR, et al: Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int J Radiat Oncol Biol Phys 44:1125-1135, 1999
36. Howle JA, Gale GR: Cis-dichlorodiammineplatinum (II): Persistent and selective inhibition of deoxyribonucleic acid synthesis in vivo. Biochem Pharmacol 19:2757-2762, 1970
37. Taylor DM, Tew KD, Jones JD: Effects of cis-dichlorodiammine platinum (II) on DNA synthesis in kidney and other tissues of normal and tumour-bearing rats. Eur J Cancer 12: 249-254, 1976
38. Corda Y, Job C, Anin MF, et al: Transcription by eucaryotic and procaryotic RNA polymerases of DNA modified at a d(GG) or a d(AG) site by the antitumor drug cis-diamminedichloroplatinum(II). Biochemistry 30:222-230, 1991
39. Stratford IJ, Williamson C, Adams GE: Combination studies with misonidazole and a cis-platinum complex: Cytotoxicity and radiosensitization in vitro. Br J Cancer 41:517-522, 1980
40. Dewit L: Combined treatment of radiation and cisdiamminedichloroplatinum (II): A review of experimental and clinical data. Int J Radiat Oncol Biol Phys 13:403-426, 1987
41. Freyer G, Bossard N, Romestaing P, et al: Addition of oxaliplatin to continuous fluorouracil, 1-folinic acid, and concomitant radiotherapy in rectal cancer: The Lyon R 97-03 phase I trial. J Clin Oncol 19:2433-2438, 2001
42. Amorino GP, Freeman ML, Carbone DP, et al: Radiopotentiation by the oral platinum agent, JM216: Role of repair inhibition. Int J Radiat Oncol Biol Phys 44:399-405, 1999
43. Rowinsky EK: The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 48:353-374, 1997
44. Hall EJ: Radiobiology for the Radiobiologist (ed 4). Lippincott, Philadelphia, PA, 1994
45. Creane M, Seymour CB, Colucci S, et al: Radiobiological effects of docetaxel (Taxotere): A potential radiation sensitizer. Int J Radiat Biol 75:731-737, 1999
46. Yang LX, Wang HJ, Holton RA: In vitro efficacy of a novel chemoradiopotentiator-Taxoltere metro. Int J Radiat Oncol Biol Phys 46:159-163, 2000
47. Altmann KH, Wartmann M, O'Reilly T: Epothilones and related structures-A new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta 1470:M79-M91, 2000
48. Nicoletti MI, Colombo T, Rossi C, et al: IDN5109, a taxane with oral bioavailability and potent antitumor activity. Cancer Res 60:842-846, 2000
49. Bristow RG, Hill RP: Molecular and cellular basis of radiotherapy, in Tannock IF, Hill RP (eds): The Basic Science of Oncology. Montreal, McGraw-Hill, 1991, pp 295-321
50. Lloyd RV, Duling DR, Rumyantsega GV, et al: Microsomal reduction of 3-amino-1,2,4-benzotriazine 1,4-dioxide to a free radical. Mol Pharmacol 40:440-445, 1991
51. Bagshaw MA: Possible role of potentiators in radiation therapy. Am J Roentgenol 85:822-833, 1961
52. Buchholz DJ, Lepak KJ, Rich TA, et al: 5-Fluorouracil-radiation interactions in human colon adenocarcinoma cells. Int J Radiat Oncol Biol Phys 32:1053-1058, 1995
53. McGinn CJ, Kinsella TJ: The experimental and clinical rationale for the use of S-phase-specific radiosensitizers to overcome tumor cell repopulation. Semin Oncol 19:21-28, 1992 (suppl 11)
54. Plunkett W, Ghandi V, Chubb S: 2′,2′-difluorodeoxycytidine metabolism and mechanism of action in human leukemia cells. Nucleosides Nucleotides 8:775-785, 1989
55. Scalliet P, Goor C, Galdermans D; Gemzar (Gemcitabine) with thoracic radiotherapy-A phase II pilot study in chemonaive patients with advanced nonsmall cell lung cancer (NSCLC). Pro Am Soc Clin Oncol 17:499a, 1998 (abstr 1923)
56. Hsiang YH, Hertzberg R, Hecht S, et al: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873-14878, 1985
57. Hsiang YH, Liu LF: Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722-1726, 1988
58. Andoh T, Ishii K, Suzuki, et al: Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci U S A 84:5565-5569, 1987
59. Iliakis G: Radiation-induced potentially lethal damage: DNA lesions susceptible to fixation. Int J Radiat Biol Relat Stud Phys Chem Med 53:541-584, 1988
60. Kirichenko AV, Rich TA: Radiation enhancement by 9-aminocamptothecin: The effect of fractionation and timing of administration. Int J Radiat Oncol Biol Phys 44:659-664, 1999
61. Takeda K, Neguro S, Kudoh S, et al: Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer. Br J Cancer 79:1462-1467, 1999
62. Choy H, MacRae R: Irinotecan in combined-modality therapy for locally advanced non-small-cell lung cancer. Oncology (Huntingt) 15:31-36, 2001 (suppl 1)
63. Fisher BJ, Scott C, Macdonald DR, et al: Phase I study of topotecan plus cranial radiation for glioblastoma multiforme: Results of Radiation Therapy Oncology Group Trial 9507. J Clin Oncol 19:1111-1117, 2001
64. Grabenbauer GG, Buchfelder M, Schrell U, et al: Topotecan as a 21-day continuous infusion with accelerated 3D-conformal radiation therapy for patients with glioblastoma. Front Radiat Ther Oncol 33:364-368, 1999
65. Maeda H, Seymour LW, Miyamoto Y: Conjugates of anticancer agents and polymers: Advantages of macromolecular therapeutics in vivo. Bioconjug Chem 3:351-362, 1992
66. Li C, Ke S, Wu QP, et al: Tumor irradiation enhances the tumor-specific distribution of poly(L-glutamic acid)-conjugated paclitaxel and its antitumor efficacy. Clin Cancer Res 6:2829-2834, 2000
67. Li C, Ke S, Wu QP, et al: Potentiation of ovarian OCa-1 tumor radioresponse by poly (L-glutamic acid)-paclitaxel conjugate. Int J Radiat Oncol Biol Phys 48:1119-1126, 2000
68. Brizel DM, Wasserman TH, Henke M, et al: Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18:3339-3345, 2000
69. Komaki R, Lee JS, Kaplan B, et al: Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: Preliminary results. Semin Radiat Oncol 12:46-49, 2002 (suppl 1)
70. Phillips KA, Tannock IF: Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy. J Clin Oncol 16:3179-3190, 1998
71. Mason KA, Komaki R, Cox JD, et al: Biology-based combined-modality radiotherapy: Workshop report. Int J Radiat Oncol Biol Phys 50:1079-1089, 2001